CDK4/6 inhibitors rechallenge post-progression in HR-positive HER2-negative advanced/metastatic breast cancer patients: a meta-analysis of Kaplan–Meier-reconstructed individual-level data
Jasmina Veta Darkovski, Isabella Michelon, Gabriela Gazzoni, Isadora Mamede, Yujin Jeong, Ludimila Cavalcante · 2026
Read CDK4/6 inhibitors rechallenge post-progression in HR-positive HER2-negative advanced/metastatic breast cancer patients: a meta-analysis of Kaplan–Meier-reconstructed individual-level data by Jasmina Veta Darkovski, Isabella Michelon, Gabriela Gazzoni, Isadora Mamede, Yujin Jeong, Ludimila Cavalcante (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13214152.txt.
Description
Jasmina Veta Darkovski and co-authors pool in 2026 the results of restarting a class of breast cancer drugs after the cancer grows through them the first time. These CDK4/6 inhibitors, paired with hormone therapy, are standard for the commonest advanced breast cancer type.
Eight trials covering 1,396 patients compared restarting a drug from the class plus hormone therapy against hormone therapy alone. Restarting stretched the time before progression from under four months to nearly six, cutting risk by about a third. Overall survival did not improve. Switching to a different drug in the class, most often abemaciclib, looked better than repeating the same one. Mutations linked to hormone resistance did not erase the benefit.
Catalog record
| CREATOR | Jasmina Veta Darkovski, Isabella Michelon, Gabriela Gazzoni, Isadora Mamede, Yujin Jeong, Ludimila Cavalcante |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |